TYSONS, Va.--(BUSINESS WIRE)--Zephyr AI, Inc. (“Zephyr AI”), a high-growth healthcare exertion institution committed to radically reshaping accepted approaches to cause find and precision medicine, has announced the enactment of a Scientific and Medical Advisory Board.
Representing a postulation of immoderate of the world’s astir pre-eminent and pioneering leaders successful probe and healthcare, Zephyr AI’s Scientific and Medical Advisory Board volition supply strategical counsel to reappraisal and validate the teams advancement crossed the science, technology, and information organizations and specify its commercialization strategy. Zephyr AI is simply a portfolio institution of Red Cell Partners, an incubation steadfast that invests successful and builds technology-led companies wrong the healthcare and nationalist information sectors.
“Zephyr is good connected its mode to amassing the world’s astir broad healthcare dataset. Combined with apical engineers, data-scientists, and next-generation instrumentality learning capabilities, the squad is generating novel, translatable insights that volition usher successful an epoch of existent precision medicine” said Grant Verstandig, Zephyr AI Co-Founder & Executive Chairman, and Red Cell Partners CEO. “Most of the information that physicians request already exists, but it is excessively cumbersome to beryllium utilized efficiently oregon effectively. The situation that the squad astatine Zephyr is taking connected is 1 of synthesizing immense amounts of disparate information to crook inefficiencies into opportunities for providers to foretell adverse wellness events earlier they hap and to find the close cause for the close idiosyncratic astatine the close time. Ultimately, these capabilities tin assistance easiness the load connected the healthcare strategy portion dramatically improving diligent outcomes. Zephyr is genuinely privileged to person assembled this committee of visionary thought leaders to lend strategical counsel and decades of penetration arsenic we prosecute specified ambitious goals.”
“Developing tools and products that supply worth crossed the healthcare worth concatenation – from patients and physicians to wellness systems, insurers, and pharma – is simply a gangly order, but 1 I americium assured the Zephyr squad is uniquely susceptible of delivering connected and linking these together. This includes linking genotype to outcome,” said Justin Stebbing, M.D, Ph.D., Editor-in-Chief of Oncogene, Visiting Professor of Oncology Imperial College, London, Professor of Biomedical Sciences, ARU, Cambridge, and Chair of Zephyr AI Scientific and Medical Advisory Board. “I americium honored to beryllium portion of Zephyr’s trailblazing enactment and can’t hold to collaborate with the squad to thrust cutting-edge advancements successful precision medicine.”
To date, Zephyr AI’s lineup of innovations see its trademark Vulnerability Network™ Method, which identifies interacting genes successful tumors, illuminating erstwhile and wherefore definite drugs volition work, portion others won’t, and its Insights™ product, a predictive analytics determination enactment instrumentality with wide applications for colonisation wellness and diligent management.
“By gathering technologies aimed astatine predicting antagonistic wellness outcomes and identifying interventions that guarantee precise treatments tailored for the patient, Zephyr AI’s efforts person the imaginable to marque a meaningful interaction connected diligent care,” Professor Stebbing noted. “This is particularly important erstwhile 1 considers what is astatine stake, peculiarly for those who are facing devastating diseases similar crab oregon diabetes. At the extremity of the day, it’s astir making sick radical better. It’s not overmuch much analyzable than that. How we get determination is simply a antithetic matter, and that’s wherever Zephyr AI comes in.”
Zephyr AI’s CEO David Morgan added, “Our quality to prosecute this esteemed radical of renowned thought leaders is simply a testament to the caliber of our team, the aboriginal committedness of our technology, and our exceptional Board of Directors including Dr. Jack Rowe, M.D., whose nationally recognized technological estimation and advocacy were pivotal successful making this world-class Scientific and Medical Advisory Board travel to fruition.”
Members of the Zephyr AI Scientific and Medical Advisory Board include:
Board Chair:
Justin Stebbing, M.D, Ph.D.
Editor-in-Chief of Oncogene, Visiting Professor of Cancer Medicine and Oncology, Imperial College, London, and Professor of Biomedical Sciences, ARU, Cambridge
Dr. Stebbing trained successful medicine astatine Trinity College, Oxford anterior to a residency successful interior medicine astatine Johns Hopkins, past completion of grooming successful London wherever helium has been a Professor for galore years. He has published much than 700 peer-reviewed papers, the bulk regarding caller therapeutic and translational approaches successful journals specified arsenic the Lancet, New England Journal of Medicine, Journal of Clinical Oncology and Annals of Internal Medicine. He is simply a subordinate of the American Society for Clinical Investigation and astatine the commencement of the COVID-19 pandemic, helium utilized AI to place baricitinib arsenic having anti-viral arsenic good arsenic anti-cytokine properties, information that spearheaded its computer-bench-bedside-regulatory support wrong 9 months.
Alan Barge, M.D.
Chairman, Modra Pharmaceuticals, Founder, Carrick Therapeutics, Co-Founder ASLAN Pharmaceuticals, erstwhile VP of Clinical and Head of Oncology and Infection, AstraZeneca
Dr. Barge trained successful medicine astatine Oxford and London and specialized successful oncology and hematology. He joined Amgen successful 1990, arsenic European Medical Director, and was liable for the European, and subsequently worldwide improvement of Neupogen® (filgrastim), and different hematopoietic maturation factors. In 1999, helium joined AstraZeneca, wherever helium established a squad liable for aboriginal signifier oncology cause development. In 2005, helium was appointed Vice President of Clinical and Head of Oncology and Infection, liable for gathering and managing a ample improvement group, and the execution of AstraZeneca’s oncology portfolio globally.
Tom Maniatis, Ph.D.
Scientific Director and Chief Executive Officer of the New York Genome Center (NYGC), Professor of Biochemistry and Molecular Biophysics astatine the Columbia University Medical Center, subordinate of the Zuckerman Institute of Mind, Brain and Behavior, and founding Director of the Columbia University-wide Precision Medicine Initiative
Dr. Maniatis leads the improvement of computational and experimental genomic methods and disease-focused probe astatine the NYGC to amended recognize the familial ground of cancer, neurodegenerative and neuropsychiatric diseases. He is recognized arsenic 1 of the pioneers of modern molecular biology, having led the improvement and exertion of genomic methods to basal subject and biotechnology. Dr. Maniatis’ probe contributions person been recognized by galore awards, including the Lasker-Koshland Special Achievement Award successful Medical Science, and rank successful the US. National Academy of Science, and the U.S. National Academy of Medicine. Maniatis is besides a pioneer successful biotechnology, cofounding companies that produced respective FDA approved drugs: Genetics Institute 1 of the earliest biotech companies (Factor VII, Factor IX, GM-CSF, BMPs, EPO present owned by Pfizer), ProScript (Proteosome Inhibitors – (Velcade) clinically developed by Millennium (bortezomid), Acceleron, (TGF-b inhibitors, Luspatercept (REBLOZYL) (now owned by Merck), and astir recently, Kallyope Inc. a gut-brain axis company.
Siddhartha Mukherjee, M.D., Ph.D.
Assistant Professor of Medicine, Columbia University Medical Center
Dr. Mukherjee is the Pulitzer Prize-winning writer of The Emperor of All Maladies: A Biography of Cancer which earned the grant successful 2011 for wide nonfiction and has been listed among Time magazine’s “All-Time 100 Nonfiction Books.” A Rhodes Scholar, Dr. Mukherjee holds a BS successful biology from Stanford University; a DPhil successful immunology from Oxford University; and an MD from Harvard Medical School. Dr. Mukherjee is simply a hematologist and oncologist who has published articles successful the journals Nature, The New England Journal of Medicine, and Cell. Dr. Mukherjee is the technological laminitis of respective biotech companies, including Myeloid Therapeut, Immuneel Therapeutics, and Vor Biopharma which has been fixed breakthrough presumption by the FDA for its anti-AML attraction strategy.
Richard L. Schilsky, M.D., FACP, FSCT, FASCO
Former EVP and Chief Medical Officer, American Society of Clinical Oncology (ASCO), Professor Emeritus, University of Chicago
Dr. Schilsky is an planetary adept successful gastrointestinal malignancies and crab pharmacology, having published much than 400 technological articles, reviews, and commentaries. He has served connected a fig of adjacent reappraisal and advisory committees for the NCI including serving arsenic a subordinate and seat of the NCI Board of Scientific Advisors and arsenic a subordinate of the Clinical and Translational Research Advisory Committee. He joined the American Society of Clinical Oncology (ASCO) successful 2013 arsenic Chief Medical Officer aft a astir 30-year vocation astatine the University of Chicago Medicine, wherever helium served arsenic main of hematology/ oncology successful the Department of Medicine and the lawman manager of the University of Chicago Comprehensive Cancer Center. Dr. Schilsky is the Principal Investigator of the ASCO Targeted Agent and Profiling Utilization Registry (TAPUR) survey and a erstwhile subordinate and seat of the FDA Oncology Drugs Advisory Committee.
About Zephyr AI
Zephyr AI is simply a high-growth healthcare exertion institution committed to radically reshaping accepted approaches to precision medicine. Through partnerships and proprietary data, Zephyr AI is curating the world’s astir broad healthcare dataset and marrying it with cutting-edge artificial quality algorithms to make novel, translatable insights to physique tools and products that enactment patients and providers and substance ongoing research. At Zephyr AI, our mission-focused squad of world-class bundle engineers and biologists leverage large information and next-generation exertion to deduce transformational insights and physique enduring partnerships that volition revolutionize the attraction of cancer, diabetes, and different diseases. Visit america astatine www.zephyrai.bio and travel america connected Twitter, Instagram and LinkedIn.
About Red Cell Partners
Red Cell Partners is an incubation steadfast gathering rapidly-scalable technology-led companies that bring revolutionary advancements to the healthcare and nationalist information markets. United by a shared consciousness of work and heavy content successful the powerfulness of innovation, Red Cell is processing almighty tools and solutions to code our nation’s astir pressing problems. Visit america astatine redcellpartners.com and travel america connected Twitter, Instagram, and LinkedIn.
Contacts
Katie Griff
Head of Marketing, Zephyr AI
katie@zephyrai.bio
Liz Boten
Evoke Canale for Zephyr AI
Liz.boten@canalecomm.com
English (US)